People  |   Processes   |   Predictions

 LIVE ONLINE 16 November 2021

Pharma Integrates 2021 Agenda

TUESDAY 16TH NOVEMBER 2021

PANEL DISCUSSIONS AND WORKSHOPS

PLEASE NOTE The agenda and timings have not been finalised so maybe subject to change.

SESSIONS WILL BE DIVIDED INTO 3 TRACKS PRIOR TO THE EVENT.

DELEGATES WILL BE FREE TO CHOOSE FROM TRACK 1, 2 or 3 AT ANY TIME.

THE DAY WILL START WITH OPENING REMARKS AND CONCLUDE WITH A

NETWORKING SESSION FINISHING AT 17:00.

Networking

Welcome

Opening remarks

Ben Osborn, President ABPI & Managing Director UK, Pfizer

Fireside Chat

An interview with: SIR JOHN BELL, Regius Professor of Medicine at Oxford University, and Chairman of the Office for the Strategic Coordination of Health Research.
Interviewed by: TREVOR JONES CBE, Director, Arix Bioscience plc and e-Therapeutics plc

PEOPLE

How do we ensure our people have the right skills and support to succeed? How do we develop the best partnerships and engage with patients?

Session 1

Home & away

Has remote working changed the culture in pharma? What will future working environments and practices look like?

Networking

Session 2

I’ve got skills, they’re multiplying

With the ambitious UK Life Science Strategy and the Brexit brain drain, how can we ensure we have the skills in place to deliver future products for patients?

Session 3

Howdy partner!

Collaboration has been imperative in delivering the next generation of medicines. How will traditional and non-traditional partnerships deliver the best therapeutics for patients?

Networking

Session 4

Power to the people

The pandemic has changed working practices. How can we ensure that we are giving our people an environment in which they can succeed?

Session 5

Waiting patiently

The pandemic has made patients much more aware, and in some cases sceptical, of medicines development. How can we engage, educate and empower patients to enable medicines to reach them more quickly?

Virtual Drinks Reception

PROCESSES

How can we adapt our processes to accelerate the development and delivery of medicines?

Session 1

I feel the need for speed

Coronavirus vaccines were developed at unprecedented speed. With growing expectations that drugs are made more quickly, how can we accelerate timelines?

Networking

Session 2

Genomics is Key

The past decade has seen genetically targeted therapies go from theory to practice, particularly in the field of oncology. Every new disease-causing gene discovered opens up a new line of attack on rare, intractable, and chronic diseases, but health systems risk multiple bottlenecks that might derail progress. While there are ethical, logistical, and scientific challenges to overcome, what might the potential opportunity be for genetically-characterised populations to accelerate research and care?

Networking

Session 3

Are you in or out?

While pharma outsourcing is still on the rise, the pandemic has led to near-shoring or activities being brought in-house to ensure milestones could be met. Where will we make our medicines in the future?

Session 4

Pharma on trial

Time is always of the essence for clinical programmes. How do we design for stratification, speed and ultimately success, and how do we make the most of clinical data?

Session 5

Underpinning the Future of Healthcare with High Performance Computing and Artificial Intelligence.

The need for a faster, more fluid research environment is driving the adoption of advanced computing technologies

Virtual Drinks Reception

PREDICTIONS

How can we predict future pharma needs and prevent the next pandemics? How can we use the current focus on pharma to demystify medicines?

Session 1

Forecasting Pharma’s future

When the pandemic is finally behind us, what will the future of health look like?

Networking

Session 2

Fast Forward – The future of Pharma Supply Chains

  • What could/should supply chains look like 10 years from now?
  • Responding to the shift towards patient centric and personalised medicine
  • What the pandemic taught us about how quickly we can build supply chains (when we have to)
  • Innovation and emerging technology trends……what tech can be deployed today and what will be needed in the future?

Session 3

In the spotlight

Previously the pharma industry has not been the most popular. Now all eyes are on us. How can we use this focus to demystify medicines and convey our impact?

Networking

Session 4

Preventing the next pandemics

As we approach the end of 2021, the prevention agenda has become more relevant than ever.
Has the pandemic set public health back? Can we do better? Better risk prediction, better prevention interventions, better distribution of funding and use of technologies to solve the problems we are facing?
How can we think creatively to reimagine public health and what will we be saying about progress in 10 years’ time?

Session 5

CDMOs Scale Up

This session will address the evolving dynamics of the CDMO industry, in particular, how the business of the “mega CDMOs” is likely to evolve, and the implications for competition among smaller and speciality CDMOs.

Virtual Drinks Reception

Networking

Welcome and Opening Remarks

PEOPLE

How do we ensure our people have the right skills and support to succeed? How do we develop the best partnerships and engage with patients?

Session 1:

Home & away

Has remote working changed the culture in pharma? What will future working environments and practices look like?

Networking

Session 2:

I’ve got skills, they’re multiplying

With the ambitious UK Life Science Strategy and the Brexit brain drain, how can we ensure we have the skills in place to deliver future products for patients?

Session 3:

Howdy partner!

Collaboration has been imperative in delivering the next generation of medicines. How will traditional and non-traditional partnerships deliver the best therapeutics for patients?

Networking

Session 4:

Power to the people

The pandemic has changed working practices. How can we ensure that we are giving our people an environment in which they can succeed?

Session 5

Waiting patiently

The pandemic has made patients much more aware, and in some cases sceptical, of medicines development. How can we engage, educate and empower patients to enable medicines to reach them more quickly?

Virtual Drinks Reception

PROCESSES

How can we adapt our processes to accelerate the development and delivery of medicines?

Session 1:

I feel the need for speed

Coronavirus vaccines were developed at unprecedented speed. With growing expectations that drugs are made more quickly, how can we accelerate timelines?

Networking

Session 2:

Genomics is Key

The past decade has seen genetically targeted therapies go from theory to practice, particularly in the field of oncology. Every new disease-causing gene discovered opens up a new line of attack on rare, intractable, and chronic diseases, but health systems risk multiple bottlenecks that might derail progress. While there are ethical, logistical, and scientific challenges to overcome, what might the potential opportunity be for genetically characterised populations to accelerate research and care?

Networking

Session 3:

Are you in or out?

While pharma outsourcing is still on the rise, the pandemic has led to near-shoring or activities being brought in-house to ensure milestones could be met. Where will we make our medicines in the future?

Session 4:

Pharma on trial

Time is always of the essence for clinical programmes. How do we design for stratification, speed and ultimately success, and how do we make the most of clinical data?

Session 5:

Underpinning the Future of Healthcare with High Performance Computing and Artificial Intelligence.

The need for a faster, more fluid research environment is driving the adoption of advanced computing technologies

Virtual Drinks Reception

PREDICTIONS

How can we predict future pharma needs and prevent the next pandemics? How can we use the current focus on pharma to demystify medicines?

Session 1:

Forecasting Pharma’s future

When the pandemic is finally behind us, what will the future of health look like?

Networking

Session 2:

Fast Forward – The future of Pharma Supply Chains

  • What could/should supply chains look like 10 years from now?
  • Responding to the shift towards patient-centric and personalised medicine
  • What the pandemic taught us about how quickly we can build supply chains (when we have to)
  • Innovation and emerging technology trends……what tech can be deployed today and what will be needed in the future?

Session 3:

In the spotlight

Previously the pharma industry has not been the most popular. Now all eyes are on us. How can we use this focus to demystify medicines and convey our impact?

Networking

Session 4:

Preventing the next pandemics

As we approach the end of 2021, the prevention agenda has become more relevant than ever.
Has the pandemic set public health back? Can we do better? Better risk prediction, better prevention interventions, better distribution of funding and use of technologies to solve the problems we are facing?
How can we think creatively to reimagine public health and what will we be saying about progress in 10 years’ time?

Session 5:

CDMOs Scale Up

This session will address the evolving dynamics of the CDMO industry, in particular, how the business of the “mega CDMOs” is likely to evolve, and the implications for competition among smaller and speciality CDMOs.

Virtual Drinks Reception

Sign up for life science integrates news

Get the latest news and updates by signing up today.

By signing up to the life science integrates newsletter, you have read and agree to our Privacy Policy, including our Cookie use.

People  |   Processes   |   Predictions

 LIVE ONLINE 16 November 2021